L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays in children and adolescents with 16p11.2 deletion syndrome.

The L16HTHOUSE Study is now underway to evaluate the safety, tolerability, and effectiveness of a new medication, monitoring the results in helping with the developmental impairments in children and adolescents with the 16p11.2 deletion.

Redenlab is partnering with the Simon’s Foundation for this important trial in children and adolescents with the 16p11.2 deletion across sites in Eastern, Western and Southern USA.

To find out more about the study, click here.